Citation

82 FR 16406

Multiple canonical documents share this first-page citation.

Prospective Grant of Start-up Exclusive Evaluation Option Patent License: “The Development and Use of Diazeniumdiolated and Hybrid Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in Humans” Tuesday, April 4, 2017 82 FR 16406
National Heart, Lung, and Blood Institute; Notice of Closed Meeting Tuesday, April 4, 2017 82 FR 16406